Arcturus Therapeutics
ARCT
143 hedge funds and large institutions have $336M invested in Arcturus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 39 reducing their positions, and 26 closing their positions.
157% more call options, than puts
Call options by funds: $5.16M | Put options by funds: $2.01M
28% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 39
19% more capital invested
Capital invested by funds: $283M → $336M (+$53.4M)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 144 → 143 (-1)
3.13% less ownership
Funds ownership: 98.14% → 95.01% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.15M |
| 2 |
DAS
Diversify Advisory Services
Sandy,
Utah
|
+$2.42M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.46M |
| 4 |
Goldman Sachs
New York
|
+$1.31M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.89M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$3.47M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$3.38M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.08M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$2.24M |
ARCT Hedge Fund Activity: Q2 2025 in Review
143 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2025, worth a combined $336M — up 19% from $283M a quarter earlier.
Fund positioning in ARCT was balanced in Q2 2025: 26 funds opened new positions, 26 closed out, 50 added to existing stakes and 39 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $4.15M. The largest seller was Millennium Management, exiting entirely with an estimated $4.89M sold.
- 143 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2025, down from 144 in Q1 2025.
- Funds reported $336M of Arcturus Therapeutics stock for Q2 2025, up 19% quarter-over-quarter.
- 26 funds opened new Arcturus Therapeutics positions in Q2 2025 and 26 closed out, a net change of 0 holders.
- The largest Arcturus Therapeutics buyer in Q2 2025 was Jacobs Levy Equity Management, an estimated $4.15M added.
- The largest Arcturus Therapeutics seller in Q2 2025 was Millennium Management, an estimated $4.89M sold.
Based on aggregated 13F filings for Q2 2025.